Testing Zanzalintinib for Advanced Bone Sarcomas
Treatments studied
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a type of bone sarcoma that has spread or cannot be removed by surgery.
- You have had at least one prior treatment for your cancer, but no more than two.
- You have not taken a similar drug (like cabozantinib, regorafenib, or pazopanib) before.
- You are generally able to care for yourself (ECOG score 0-2) and weigh at least 40 kg (88 lbs).
- Your kidneys, liver, and blood counts are within certain safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether a new combination of two drugs, zanzalintinib and pembrolizumab, can help people with certain types of advanced soft-tissue sarcoma that have not responded to other treatments. It aims to find out if the combination is safe and effective.
This study tests a new targeted drug called zanzalintinib for patients with olfactory neuroblastoma (a rare cancer in the nasal cavity) that has come back or spread. The drug blocks proteins that help tumors grow, and this trial will see if it can help patients who cannot have surgery or radiation.
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
This trial studies an experimental drug called zanzalintinib for people with adenoid cystic carcinoma that has spread or come back. The goal is to see if the drug can shrink tumors or slow the disease.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial tests an oral drug called zanzalintinib in people with pheochromocytoma or paraganglioma that has spread or cannot be removed by surgery and has gotten worse. The goal is to see if the drug can slow or stop tumor growth.
Hear when a new Bone Sarcomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.